RANKL
17 drugs Oncology
4
approved indications
17
Approved Drugs
9
Companies
8
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (9 companies)
✓ All 17 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (8 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Novartis 2 drugs
BIOCON BIOLOGICS INC 2 drugs
CELLTRION INC 2 drugs
By Therapeutic Area
Oncology 17 drugs
Drugs by Company PRO
Fresenius Kabi 2 drugs
SAMSUNG BIOEPIS CO LTD 1 drug
By Therapeutic Area
Oncology 17 drugs
JUBBONTI, WYOST, AUKELSO, OSPOMYV +13 more
Indications Treated
OsteoporosisGlucocorticoid-Induced OsteoporosisProstate CancerBreast CancerMultiple MyelomaBone MetastasisGiant Cell Tumor of BoneHypercalcemia of Malignancy
All Drugs Targeting RANKL
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| JUBBONTI | Novartis | 2024 | 4 | Oncology |
| WYOST | Novartis | 2024 | 4 | Oncology |
| AUKELSO | BIOCON BIOLOGICS INC | 2025 | 4 | Oncology |
| OSPOMYV | SAMSUNG BIOEPIS CO LTD | 2025 | 4 | Oncology |
| OSENVELT | CELLTRION INC | 2025 | 4 | Oncology |
| BILPREVDA | SHANGHAI HENLIUS BIOTECH | 2025 | 4 | Oncology |
| BILDYOS | SHANGHAI HENLIUS BIOTECH | 2025 | 4 | Oncology |
| XTRENBO | Hikma | 2025 | 4 | Oncology |
| PROLIA | Amgen | 2010 | 4 | Oncology |
| XGEVA | Amgen | 2010 | 4 | Oncology |
| CONEXXENCE | Fresenius Kabi | 2025 | 4 | Oncology |
| BOMYNTRA | Fresenius Kabi | 2025 | 4 | Oncology |
| OZILTUS | AMNEAL PHARMS LLC | 2025 | 4 | Oncology |
| BOSAYA | BIOCON BIOLOGICS INC | 2025 | 3 | Oncology |
| STOBOCLO | CELLTRION INC | 2025 | 3 | Oncology |
| ENOBY | Hikma | 2025 | 3 | Oncology |
| BONCRESA | AMNEAL PHARMS LLC | 2025 | 3 | Oncology |